Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

0.7657 -0.0243 (-3.08%)
Streaming Delayed Price Updated: 2:08 PM EDT, Jun 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 620,807
Open 0.7900
Bid (Size) 0.7656 (9)
Ask (Size) 0.7657 (13)
Prev. Close 0.7900
Today's Range 0.7445 - 0.7900
52wk Range 0.6603 - 2.430
Shares Outstanding 115,907,216
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)
– First patient dosed in a Phase 1b/2 study evaluating STC-15, a METTL3 inhibitor, in combination with LOQTORZI, a next-generation PD-1 inhibitor – 
From Coherus BioSciences, Inc.
Via GlobeNewswire
Top movers in Friday's after hours session
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill

Performance

YTD
-45.3%
-45.3%
1 Month
-4.3%
-4.3%
3 Month
-16.4%
-16.4%
6 Month
-55.0%
-55.0%
1 Year
-53.3%
-53.3%

More News

Read More
Which stocks are moving before the opening bell on Tuesday?
Via Chartmill
Earnings Scheduled For May 12, 2025
Via Benzinga
Earnings Preview: Coherus BioSciences
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus to Participate in Upcoming Investor Conferences
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025
From Coherus BioSciences, Inc.
Via GlobeNewswire
Which stocks are moving after the closing bell on Wednesday?
Via Chartmill
Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update
From Coherus BioSciences, Inc.
Via GlobeNewswire
Earnings Scheduled For March 10, 2025
Via Benzinga
Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
From Coherus BioSciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Is Coherus BioSciences Stock Trading Higher On Tuesday?
Via Benzinga
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference
From Coherus BioSciences, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Coherus Oncology, Inc. - Common Stock publicly traded?
Yes, Coherus Oncology, Inc. - Common Stock is publicly traded.
What exchange does Coherus Oncology, Inc. - Common Stock trade on?
Coherus Oncology, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Coherus Oncology, Inc. - Common Stock?
The ticker symbol for Coherus Oncology, Inc. - Common Stock is CHRS on the Nasdaq Stock Market
What is the current price of Coherus Oncology, Inc. - Common Stock?
The current price of Coherus Oncology, Inc. - Common Stock is 0.7657
When was Coherus Oncology, Inc. - Common Stock last traded?
The last trade of Coherus Oncology, Inc. - Common Stock was at 06/17/25 02:08 PM ET
What is the market capitalization of Coherus Oncology, Inc. - Common Stock?
The market capitalization of Coherus Oncology, Inc. - Common Stock is 88.75M
How many shares of Coherus Oncology, Inc. - Common Stock are outstanding?
Coherus Oncology, Inc. - Common Stock has 89M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.